Friday 6 November 2026 Export LLY’s income statement to Excel — free account

Eli Lilly and Company

LLY Healthcare Drug Manufacturers General

Eli Lilly and Company’s revenue for fiscal 2025 (year ended December 2025) was $65.2 billion, up 44.7% from fiscal 2024.

Revenue: +38.6%
EPS: +16.3%
Free cash flow: +21.8%
Total debt: +15.0%

Quarter to September 2026, against a year earlier

1,370.24 47.75 −3.37%

Follow LLY

Alert me

Market cap: $1.28T
P/E: 44.5×
Fwd P/E: 41.5×
Dividend yield: 0.49%
F-score: 7/9
Altman Z: 8.61
Beneish M: −1.91
Dividend safety: 86/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Eli Lilly and Company (LLY) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, Eli Lilly and Company (LLY) trades at a P/S ratio of 14.1×. Over the past ten years it has ranged from 3.3× (December 2016) to 22.8× (June 2024); the current reading is higher than 82% of that period. That is above the Drug Manufacturers General industry median of 3.5× and above the Healthcare sector median of 3.5×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/LLY/ps-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Eli Lilly and Company P/S ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/LLY/metrics/ps-ratio">Eli Lilly and Company (LLY) P/S ratio — stockrow.com</a></p>

Period	P/S ratio	Change
FY2025	14.8×	(4.15%)
FY2024	15.4×	(1.20%)
FY2023	15.6×	35.48%
FY2022	11.5×	30.35%
FY2021	8.8×	41.66%
FY2020	6.2×	13.90%
FY2019	5.5×	(0.92%)
FY2018	5.5×	24.06%
FY2017	4.5×	19.89%
FY2016	3.7×	(17.02%)

Period	P/S ratio	Change
Sep 2026	11.9×	(11.16%)
Jun 2026	13.4×	17.99%
Mar 2026	11.4×	(23.03%)
Dec 2025	14.8×	28.46%
43 more quarters	Free account

Against its own ten years

Low 3.3× High 22.8×

Ten-year median 6.4×

Current reading's percentile 80

Company	P/S ratio
PFE Pfizer Inc. compare	2.7×
AZN AstraZeneca PLC compare	4.7×
NVS Novartis AG compare	5.4×
MRK Merck & Co., Inc. compare	5.4×
AMGN Amgen Inc. compare	6.4×
JNJ Johnson & Johnson compare	6.6×
GILD Gilead Sciences, Inc. compare	6.7×
ABBV AbbVie Inc. compare	7.7×
LLY Eli Lilly and Company	14.1×
Drug Manufacturers General industry median	3.5×
Healthcare sector median	3.5×
Market median	1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

Eli Lilly and Company (LLY) P/S ratio

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on LLY

P/S ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/S ratio against peers

What P/S ratio is

More on LLY

Stockrow Weekly